376
Participants
Start Date
December 28, 2023
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
Ribociclib
There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
Combination chemotherapy
There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Moscow
RECRUITING
Novartis Investigative Site, Podolsk
RECRUITING
Novartis Investigative Site, Moscow Region Istra Village
RECRUITING
Novartis Investigative Site, Yaroslavl
RECRUITING
Novartis Investigative Site, Tver'
RECRUITING
Novartis Investigative Site, Kaluga
RECRUITING
Novartis Investigative Site, Krasnodar
RECRUITING
Novartis Investigative Site, Nal'chik
RECRUITING
Novartis Investigative Site, Vladikavkaz
RECRUITING
Novartis Investigative Site, Tambov
RECRUITING
Novartis Investigative Site, Izhevsk
RECRUITING
Novartis Investigative Site, Saransk
RECRUITING
Novartis Investigative Site, Ufa
RECRUITING
Novartis Investigative Site, Chelyabinsk
RECRUITING
Novartis Investigative Site, Yekaterinburg
RECRUITING
Novartis Investigative Site, Kemerovo
RECRUITING
Novartis Investigative Site, Barnaul
RECRUITING
Novartis Investigative Site, Krasnoyarsk
RECRUITING
Novartis Investigative Site, Irkutsk
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY